{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:38:45Z","timestamp":1776713925947,"version":"3.51.2"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.clinthera.2006.02.007","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T11:13:20Z","timestamp":1147173200000},"page":"151-173","source":"Crossref","is-referenced-by-count":74,"title":["Update of current therapeutic options for the treatment of postmenopausal osteoporosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Solomon","family":"Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.02.007_bib1","series-title":"Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis","first-page":"646","volume":"94","year":"1993"},{"key":"10.1016\/j.clinthera.2006.02.007_bib2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","article-title":"Guidelines for diagnosis and managmeent of osteoporosis","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib3","first-page":"31","article-title":"Osteoporosis. An overview of the National Osteoporosis Foundation clinical practice guide","volume":"55","author":"Heinemann","year":"2000","journal-title":"Geriatrics."},{"key":"10.1016\/j.clinthera.2006.02.007_bib4","author":"World Health Organization"},{"key":"10.1016\/j.clinthera.2006.02.007_bib5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jbmr.5650100517","article-title":"Prevalence of low femoral bone density in older U.S. women from NHANES III","volume":"10","author":"Looker","year":"1995","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib6","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","article-title":"Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.151.10.2026","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib8","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1359\/jbmr.2000.15.12.2309","article-title":"Who has osteoporosis? A conflict between clinical and public health perspectives","volume":"15","author":"Melton","year":"2000","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2106\/00004623-197860070-00010","article-title":"Survival and ambulation, following hip fracture","volume":"60","author":"Miller","year":"1978","journal-title":"J Bone Joint Surg Am."},{"key":"10.1016\/j.clinthera.2006.02.007_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/bmj.320.7231.341","article-title":"Quality of life related to fear of falling and hip fracture in older women: A time trade off study","volume":"320","author":"Salkeld","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.02.007_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00198-003-1547-4","article-title":"Health-related quality of life and radiographic vertebral fracture","volume":"15","author":"Cockerill","year":"2004","journal-title":"Obsteopros Int"},{"key":"10.1016\/j.clinthera.2006.02.007_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00198-004-1615-4","article-title":"Back pain, disability, and radiographic vertebral fracture in European women: A prospective study","volume":"15","author":"O'Neill","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2003.18.6.1139","article-title":"Adverse outcomes of osteoporotic fractures in the general population","volume":"18","author":"Melton","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bone.2004.03.035","article-title":"Health care costs of women with symptomatic vertebral fractures","volume":"35","author":"Puffer","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib18","author":"American Cancer Society","year":"2003","journal-title":"Breast Cancer Facts and Figures"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2006.02.007_bib19","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/PL00004156","article-title":"The epidemiology of osteoporosis","volume":"9","author":"Cooper","year":"1999","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s001980170131","article-title":"Acute and longterm increase in fracture risk after hospitalization for vertebral fracture","volume":"12","author":"Johnell","year":"2001","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib21","series-title":"Premarin [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.02.007_bib22","series-title":"Evista [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2006.02.007_bib23","series-title":"Miacalcin [package insert]","year":"2003"},{"key":"10.1016\/j.clinthera.2006.02.007_bib24","series-title":"Actonel [package insert]","year":"2002"},{"key":"10.1016\/j.clinthera.2006.02.007_bib25","series-title":"Fosamax [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.02.007_bib26","series-title":"Forteo for injection [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.02.007_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D3 and calcium to prevent hip fractures in the elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","article-title":"Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial","volume":"124","author":"Lips","year":"1996","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.326.7387.469","article-title":"Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial","volume":"326","author":"Trivedi","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.02.007_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/bmj.330.7498.1003","article-title":"Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care","volume":"330","author":"Porthouse","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.02.007_bib32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(05)63013-9","article-title":"Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebocontrolled trial","volume":"365","author":"Grant","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.02.007_bib33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archinte.162.6.665","article-title":"Bone mass response to discontinuation of long-term hormone replacement therapy: Results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Safety Follow-up Study","volume":"162","author":"Greendale","year":"2002","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00042192-199906040-00003","article-title":"Effect of age on reasons for initiation and discontinuation of hormone replacement therapy","volume":"6","author":"Ettinger","year":"1999","journal-title":"Menopause"},{"key":"10.1016\/j.clinthera.2006.02.007_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/cmt.6.2.96.103","article-title":"Factors affecting longterm adherence to hormone replacement therapy after screening for osteoporosis","volume":"6","author":"Steel","year":"2003","journal-title":"Climateric."},{"key":"10.1016\/j.clinthera.2006.02.007_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1010019410881","article-title":"Mechanism of action and preclinical profile of raloxifene: A selective estrogen receptor modulator","volume":"2","author":"Bryant","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.clinthera.2006.02.007_bib37","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1210\/en.140.12.5828","article-title":"Comparative analyses of mechanistic differences among antiestrogens","volume":"140","author":"Wijayaratne","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.02.007_bib38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib39","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jc.87.8.3609","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopousal women with osteoporosis: Four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.02.007_bib40","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal os-teoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev."},{"key":"10.1016\/j.clinthera.2006.02.007_bib41","first-page":"1","article-title":"Therapeutic equivlence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.clinthera.2006.02.007_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2006.02.007_bib43","first-page":"S1","article-title":"2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada","volume":"167","author":"Brown","year":"2002","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2006.02.007_bib44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2006.02.007_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence Of Osteoporotic Fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib46","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0002-9343(00)00539-8","article-title":"What PROOF proves about calcitonin and clinical trials","volume":"109","author":"Cummings","year":"2000","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: A clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.02.007_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2006.02.007_bib49","doi-asserted-by":"crossref","first-page":"479S","DOI":"10.1016\/8756-3282(95)00259-6","article-title":"Human pharmacokinetics of tiludronate","volume":"17","author":"Sansom","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib50","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2125.1999.00035.x","article-title":"The effect of dosing regimen on the pharmacokinetics of risedronate","volume":"48","author":"Mitchell","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.02.007_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib53","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: From the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib55","first-page":"1293","article-title":"Pharmacologic prevention of osteoporotic fractures","volume":"70","author":"Zizic","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2006.02.007_bib56","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib57","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.02.007_bib58","first-page":"46","article-title":"The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial","volume":"101","author":"Black","year":"1999","journal-title":"Int J Clin Pract Suppl."},{"key":"10.1016\/j.clinthera.2006.02.007_bib59","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib60","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1023\/A:1016495221567","article-title":"What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates","volume":"47","author":"Graham","year":"2002","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.clinthera.2006.02.007_bib61","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","author":"Kendler","year":"2004","journal-title":"Maturitas."},{"key":"10.1016\/j.clinthera.2006.02.007_bib63","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2006.02.007_bib64","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.clinthera.2006.02.007_bib65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.02.007_bib66","first-page":"S45","article-title":"Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib67","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest."},{"key":"10.1016\/j.clinthera.2006.02.007_bib68","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib72","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1359\/JBMR.0301228","article-title":"Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses","volume":"19","author":"Delmas","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib73","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM200105313442214","article-title":"The effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"Goodman","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib74","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM200105313442214","article-title":"The effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"Royce","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib75","first-page":"1721","article-title":"The effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"Schott","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib77","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of metaanalyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev."},{"key":"10.1016\/j.clinthera.2006.02.007_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2006.02.007_bib79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib80","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib81","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib82","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administed daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chsnut","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib83","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib84","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib85","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib86","first-page":"504","article-title":"Bisphosphonates in the treatment of osteoporosis. Principles and efficacy","volume":"151","author":"Papapoulos","year":"2000","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.clinthera.2006.02.007_bib87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2710.2004.00584.x","article-title":"Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis","volume":"29","author":"Cauza","year":"2004","journal-title":"J Clin Pharm Ther."},{"key":"10.1016\/j.clinthera.2006.02.007_bib88","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1523-1755.2000.00890.x","article-title":"Pamidronate therapy as prevention of bone loss following renal transplantation","volume":"57","author":"Fan","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jbspin.2004.08.011","article-title":"Benefits of pamidronate in children with osteogenesis imperfecta: An open prospective study","volume":"72","author":"Forin","year":"2005","journal-title":"Joint Bone Spine."},{"issue":"Suppl 21","key":"10.1016\/j.clinthera.2006.02.007_bib90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37421","article-title":"Preclinical pharmacology of zoledronic acid","volume":"29","author":"Green","year":"2002","journal-title":"Semin Oncol."},{"key":"10.1016\/j.clinthera.2006.02.007_bib91","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib92","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions, of multiple myeloma: A phase III, doubleblind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.clinthera.2006.02.007_bib93","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.clinthera.2006.02.007_bib94","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clinthera.2006.02.007_bib95","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib96","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1185\/030079904125003683","article-title":"The HORIZOn Recurrent Fracture Trial: Design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair","volume":"20","author":"Colon-Emeric","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.clinthera.2006.02.007_bib97","series-title":"Zometa for intravenous injection [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.02.007_bib98","series-title":"Aredia for injection [package insert]","year":"2005"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.02.007_bib99","first-page":"S118","article-title":"Novel ibandronate regimens in postmenopausal osteoporosis: Design of the Dosing IntraVenous Administration (DIVA) study","volume":"15","author":"Sambrook","year":"2004","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib100","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib101","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib102","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-67-6-1294","article-title":"Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course","volume":"67","author":"Rao","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2006.02.007_bib103","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01621906","article-title":"Human parathyroid peptide treatment of vertebral osteoporosis","volume":"3","author":"Reeve","year":"1993","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.clinthera.2006.02.007_bib104","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1\u201334) are predicted by duration of hormone exposure","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2006.02.007_bib105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcb.10490","article-title":"Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone","volume":"89","author":"Locklin","year":"2003","journal-title":"J Cell Biochem."},{"key":"10.1016\/j.clinthera.2006.02.007_bib106","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib107","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1210\/endo-117-4-1632","article-title":"Binding of intact parathyroid hormone to rat osteosarcoma cells: Major contribution of binding sites for the carboxyl-terminal region of the hormone","volume":"117","author":"Rao","year":"1985","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.02.007_bib108","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1\u201384) in increasing bone mineral density in postmenopausal osteoporosis","volume":"88","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.02.007_bib109","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1210\/jc.86.5.1890","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"86","author":"Harris","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.02.007_bib110","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: A randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.02.007_bib111","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/jc.87.3.985","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.clinthera.2006.02.007_bib112","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib113","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib114","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1359\/jbmr.2001.16.7.1300","article-title":"Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat","volume":"16","author":"Zhou","year":"2001","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib115","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib116","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib117","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.clinthera.2006.02.007_bib118","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.clinthera.2006.02.007_bib119","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/jc.85.6.2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T18:36:58Z","timestamp":1555612618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0149291806000476"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.02.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}